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Immunoaffinity enrichment of proteotypic peptides, coupled with selected reaction monitoring, enables
indirect protein quantification. However the lack of suitable antibodies limits its widespread application.
We developed a method in which multi-specific antibodies are used to enrich groups of peptides, thus
facilitating multiplexed quantitative protein assays. We tested this strategy in a pharmacokinetic
experiment by targeting a group of homologous drug transforming proteins in human hepatocytes. Our
results indicate the generic applicability of this method to any biological system.
S
elected reaction monitoring (SRM) is a valuable tool in targeted proteomic approaches1. Proteins in
biological samples are enzymatically fragmented down to peptides. Then peptides are chromatographically
separated and analyzed by a triple quadrupole (QQQ) mass spectrometer. Here selected peptide precursor
ions of target proteins are selectively isolated. The precursor ions are subsequently fragmented in a collision cell.
Proteins are then indirectly identified and monitored by a second filter process for peptide-specific secondary ions
(transitions). Indirect protein quantification is achieved by simultaneously measuring a defined, spiked amount
of corresponding isotopically-labeled (C13/N15) reference peptide2. The sample consumption is low and a high
number of proteins can be analyzed in parallel3. This type of mass spectrometric measurement is highly precise.
However, the release of the selected proteotypic peptide during proteolysis can vary and has to be investigated
target by target. Therefore, the quantification derived from the reference peptide is not absolute; however,
quantification is in fact absolute when complete tryptic fragmentation without a single missed cleavage site is
achieved. The use of metabolically labelled recombinant proteins will improve this in future, since a protein
standard undergoes all sample processing steps4. However, the sensitivity of SRM-based protein assays is limited:
this is caused e.g. by ion suppression effects that arise from the sample amount and complexity5. Peptide-specific
antibody sets are used in a parallelized immunoprecipitation step to reduce sample complexity and thereby
concurrent suppression effects. As a consequence sensitivity and throughput is greatly increased6,7. Although this
method does not match the speed and sample throughput of other antibody-based methods, such as sandwich
immunoassays8, its specificity is excellent. This highly specific protein detection is based on two independent lines
of evidence: immunoaffinity capture and MS/MS readout. However, broad application of this immunoaffinity MS
strategy in proteomic experiments has been restrained by the lack of suitable antibodies. The shortage of specific
antibodies is still a limiting factor although rapid progress is being made in large-scale projects targeting the
generation of antibodies on a proteomic-wide scale9,10.
Recently we demonstrated that antibodies with a short C-terminal peptide epitope (triple X proteomics
antibody) can be applied to enrich peptides that have a common C-terminal motif11. This strategy substantially
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of antibody with SRM to create a quantitative assay set-up for pro-
filing key molecules of the hepatic drug metabolism in human which
are relevant to preclinical research and drug-drug interaction profil-
ing: the subfamily CYP3A of the human cytochrome P450 enzymes
(CYP) and the ATP-binding cassette (ABC) transporter multidrug-
resistance protein 1 (MDR1/P-glycoprotein). Several publications
have described SRM-based assays for the quantification of the cyto-
chrome P450 enzymes (CYP) in liver, hepatocytes and hepatoma cell
lines13–17. The approaches described involve laborious, time-consuming
steps during the preparation of microsomes for enrichment of the low
expressed CYP isoforms as required for a reliable quantification.
Moreover, CYPs or other low abundant proteins can be enriched by
their molecular weight, using SDS-polyacrylamide electrophoresis and
quantified by LC-SRM-MS(/MS) analysis17,18. We have established a
method for quantifying three homologous CYP enzymes (CYP3A4/
43, CYP3A5, CYP3A7) and the drug transporter multidrug-resistance
protein 1 (MDR1) directly from a low amounts of human hepatocyte
lysates: only one TXP-antibody is required in the immunoaffinity
enrichment step prior to MS-based quantification.
Results
First, we performed a C-terminal-anchored alignment of all peptide
sequences derived from an in-silico tryptic digest of the CYP3A sub-
family relevant for main drug transforming processes19. We iden-
tified three peptides that were suitable for SRM analysis:
LQEEIDAVLPNK, EIDAVLPNK and EIDTVLPNK. Each of them
carry the C-terminus LPNK. Further bioinformatic analysis revealed
that a proteotypic fragment of the drug transporter MDR1 also con-
tains this sequence and can be captured by an anti-LPNK-antibody.
This multi-specific antibody (Figure 1a) was generated and purified
as described previously11. We employed the synthetic peptide of each
target to identify the optimal transitions to be monitored (see
Supplemental Table 1 and 2 for transitions of the respective pep-
tides). Three transitions, per peptide were defined for unequivocal
peptide detection and the most intensive was selected to be the
‘quantifier’ transition. It should be noted, that the peptide
LQEEIDAVLPNK is also present in the sequence of the enzyme
CYP3A43. However, no or only very low expression in hepatocytes
respectively liver was observed previously14,20.
To analyze the performance and the impact of multi-specific
immunoprecipitation, we compared the results generated by means
of a standard LC-SRM method with the TXP-LC-SRM method
which uses the antibody specific for LPNK. We thus digested
20 mg protein extract from human hepatocytes using trypsin as the
fragmenting reagent. The processed sample was divided and ana-
lyzed side by side with the two different workflows. Only the more
abundant enzyme, CYP3A4/43 and CYP3A5 could be unambigu-
ously identified and quantified through the LC-SRM-based method
without any enrichment step. Either no transition or only one was
observed in the case of the CYP3A7- and MDR-1-specific peptides:
thus, they could not be quantified. With the TXP-SRM approach, all
three transitions were detectable and all four proteins were quan-
tified (Supplemental Table 3, Figure 2, Supplemental Figure 1A–C)
from the hepatocyte extract. This increase in sensitivity can be
explained by the dramatic decrease of peptide complexity, which
reduces ion suppression effects.
Matrix effects on the two different workflows were studied using
four different amounts of hepatocyte extract (1, 5, 10 and 25 mg
total protein). In the TXP-SRM workflow, the signal intensity of
the reference peptide was not affected by the amount of initial
sample load. This demonstrates that the quality of signal and
quantification is greatly improved by introducing a rapid immu-
nopreciptitation step before LC-SRM analysis (Figure 3,
Supplemental Figure 2). In contrast, in the LC-SRM workflow
the increasing amounts of tryptically-fragmented hepatocyte sam-
ple resulted in decreasing signal intensity of the internal reference;
whereas, the signal intensity of the endogenous peptide increased
(Figure 3). This shows that the relation between the sample quant-
ity (endogenous peptide) and the peptide standard needs to be
carefully adjusted before routine quantification exclusively using
LC-SRM is done. In the TXP-SRM approach it is not necessary to
balance sample amount and internal standard because no signal
suppression was observed. Moreover, we compared transition ion
intensity ratios for each peptide since this is an additional mean for
the evaluation of the specificity in peptide quantification by single
reaction monitoring5. These ratios resulting from the endogenous
and the synthetic peptide should not differ from each other.
However, in some cases components of the sample influence these
ratios by co-eluting molecules generating interferences in one of
the monitored transitions. We observed no such interferences for
any of the immunoprecipitated peptides (Supplemental Table 4).
However, in the LC-SRM approach only the CYP3A4 peptide
surrogate achieved acceptable values (Supplemental Table 3).
Since most antibody-based immunoassay approaches target only
one molecule, our aim was to demonstrate how an antibody can
capture four different analyte peptides with equal efficiency.
Therefore, we mixed 1 pmol of each standard peptide (non-labelled
version) with 1 mg antibody and analyzed the captured fraction by
eluting the peptides into the same amount of standard peptide (iso-
topically-labelled version). We observed for each peptide an amount
of 400 fmol of the initial peptide quantity in the eluate by forming the
signal ratio of labeled-to non-labeled peptide. In sum for all four
peptides the antibody’s capacity was 1.6 pmol LPNK-peptide per
mg antibody. The theoretical number of binding sites for one mg
antibody is 13 pmol and if this number is used, the antibody’s capa-
city is 12%. More importantly, we found no evidence of preference
towards one of the four peptides, which demonstrates that peptide
group-specific enrichment of analytes with a shared epitope is feas-
ible. (Supplemental Figure 3).
We also determined the technical intra- and inter-day variation. A
10 mg hepatocyte protein extract from one hepatocyte donor was
processed and analyzed three times on the same day for variance
calculation. We calculated the inter-day variation of three independ-
ent experiments carried out on three different days. Depending on
the analyte, intra-day variation ranged from 6 to 11% and inter-day
variation from 9 to 19% (detailed values are given in table 1).
The lower limit of quantification (LLOQ) was determined in an
analyte-free commercially available buffer preparation containing
proteolytically fragmented gelatine. The LLOQ was determined
according to the FDA’s recommendation for bioanalytical method
validation21. Thus, the mean value for accuracy (variation) and pre-
cision (recovery) should be within 15%. An LLOQ is reached when
values exceed 20%. Starting from 100 nM, isotopically-labeled pep-
tides were serially diluted eight times at a ratio of 153 in digested fish
gelatine, while sequence-identical endogenous peptides were kept
constant at a concentration of 10 nM. Experiments were performed
in triplicate. After precipitation by the anti-LPNK antibody, the pep-
tides were measured by targeted selected ion monitoring (tSIM),
using high-resolution tandem mass spectrometry (LC-MS/MS,
QExactive). While the LLOQ for the MDR1 peptide was reached at
140 pM or 1.4 fmol absolute peptide amount, the limits for the
CYP3A4/A43, Cyp3A5 and CYP3A7 were three times lower and
46 pM or 460 amol peptide (Supplemental Figure 4).
To investigate the specificity of the antibody (on- and off-target
binding), we analyzed an immunoprecipitated peptide pool, starting
with 50 mg hepatocyte protein extract using non-targeted liquid
chromatography high resolution tandem mass spectrometry (LC-
MS/MS, Q Exactive). In addition to two analytes, CYP 3A4 and
MDR-1 described above, the experiment revealed 8 peptides contain-
ing the targeted LPNK motif at the C-terminus (Figure 1b and c,
Supplemental Table 5). The surrogate peptides for CYP3A5 and 3A7
were not detected in these analyses. We also identified 89 additional
www.nature.com/scientificreports
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peptides with different motifs for one amino acid and six peptides
differing in two amino acids. This mainly affected leucine and pro-
line. Our findings provide evidence for a strong preference for
LPNK-motif binding (Figure 1b).
We applied this multiplex assay in a pharmacokinetic experiment.
Primary hepatocytes were treated over a three-day period with two
different statins, pravastatin and atorvastatin. Cells were harvested
after 6, 12, 24, 48, and 72 hours and analysed with the established
TXP-SRM assay (Figure 4). Atorvastatin is known to induce
CYP3A4 via the nuclear pregnane X receptor (PXR)22. CYP3A4
expression is not influenced by pravastatin treatment, as Feidt et
al. described22. The impact of atorvastatin and pravastatin on the
protein expression of CYP3A5, CYP3A7 and MDR-1 has not been
described so far. In our experiment we observed no induction of the
monitored enzymes and the transporter in the pravastatin-treated
cells, as compared to the solvent control (DMSO) (Figure 4a–d). We
observed three-fold and ten-fold induction of CYP3A4 (Figure 4a)
and 3A7 (Figure 4c) by atorvastatin, with a peak after 24 h however,
CYP3A5 was not affected (Figure 4b). A late two- to three-fold
induction by atorvastatin was observed in MDR-1 protein expression
over time (Figure 4d). Our results confirm prior findings relating to
mRNA expression and enzymatic activity analyses for CYP3A4
induction by atorvastatin. To our knowledge, we are the first to
report an increase in CYP3A7 and MDR-1 protein levels after ator-
vastatin treatment (Figure 4c and d). The induction mechanism most
likely involves the PXR mediated transcriptional regulation because
functional PXR binding sites in the 59–flanking region of both genes
were identified previously23,24.
Discussion
We established a new multiplex MS-based immunoassay (TXP-
SRM) using one antibody. The antibody’s specificity towards the
short C-terminal peptide sequence LPNK allows the quantification
of three drug metabolizing enzymes and one drug transporter from a
minute amount of sample. Through an analysis of statin-treated
human hepatocytes, we indicated the relevance of this method to
pharmacokinetic investigations. By introducing a rapid immunoaf-
finity step into the LC-SRM-workflow sensitivity was improved
more than ten-fold and a direct analysis of the transporter and the
three drug-metabolizing enzymes without membrane fractionation
or microsome preparation facilitated. In typical induction experi-
ments the cytochrome isoforms 1A2, 2B6, 2C8, 2C9, 2C19, and
2E1 are investigated in addition to CYP 3A4 by mRNA expression
analyses and/or activity assays25. Future immunizations targeting the
termini FSGR (2B6, 2C8, and 2E1), LAER (2C9 and 2C19) and VIGR
(1A2) will allow assay development for those enzymes. These assays
might allow the monitoring of induction kinetics of a larger cyto-
chrome P450 set on protein level, because problems caused by
enzyme inhibition or mRNA degradation are avoided.
Apart from the analysis of homologue protein families, the
strength of this approach lies in its generic applicability to any bio-
logical system as it offers the advantage of using a small number of
antibodies for the quantification of a large number of proteins.
Methods
Isolation and cultivation of primary human hepatocytes. Primary hepatocytes were
isolated and cultured as described previously26. Preparations from human liver
resections from patients undergoing partial hepatectomy were performed according
to the guidelines of the charitable state-controlled foundation HTCR (Human Tissue
and Cell Research) Regensburg, Germany and the institutional guidelines for liver
resections of tumor patients with primary or secondary liver tumors, Technical
University Munich, MRI, Munich, Germany. The scientific use of human hepatocytes
was approved by the local ethics committees of the Ludwig-Maximilians-University
of Munich27 and the Technical University Munich, MRI, Munich28, Germany.
Written informed consent was obtained from all patients.
Hepatocytes were plated at a density of 1.5 * 106 cells/well on collagen-coated 6-
well plates. Cells were allowed to settle down to the collagen layer. Culture media was
replaced by serum-free Williams Medium E (Pan-Biotech-GmbH), supplemented

























































LPNK 10 70 14
LWNK 5 35 14
LINK 10 129 8
LYNK 5 67 7
LVNK 7 102 7
IPNK 3 44 7
VPNK 3 49 6
LTNK 5 93 5
LANK 6 112 5
LFNK 4 81 5
LGNK 6 126 5
LLNK 9 195 5
LMNK 2 44 5
FANK 2 50 4
IFNK 2 54 4
LNNK 3 88 3
LSNK 4 124 3
LENK 5 165 3
LPGK 5 177 3
LPNR 2 73 3
LDNK 2 75 3
LQNK 3 128 2
ILNK 2 103 2
Figure 1 | (a) Peptide group-specific antibodies. TXP antibodies target peptide subsets of global tryptic digests that share the same terminus.
(b) Frequency of C-termini in a peptide pool immunoprecipitated by the antibody anti-LPNK. Peptides were immunoprecipitated from 50 mg tryptically
digested hepatocyte and analyzed by high resolution tandem-mass spectrometry. Theoretical number of peptides harboring the respective C-termini were
calculated from an in silico digest of the Uniprot database (UniProt Homo Sapiens Reference Proteome Set database (2014 Release 1)). (c) Amino acid
frequency in the binding motif of the antibody, calculated based on the high resolution tandem-mass spectrometry analysis.
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started, cells were starved for 24 h at 37uC in a humidified chamber with 95%/5% air/
CO2, penicillin/streptomycin (100 U/mL), stabilized L-glutamine (2 mM), dexa-
methasone dihydrogenphosphate (0.025% (v/v)) and ITS-X (5 mg insulin, 3.35 mg
sodium-selenite, 2.75 mg transferrin and 1 mg ethanolamine)(Invitrogen), further
referred to as SFM.
Cells were treated with 60 mM atorvastatin 30 mM pravastatin and solvent control
(DMSO) in SFM for 6, 12, 24, 48, and 72 hours. Cells were harvested in PBS, sup-
plemented with protease inhibitors (Roche, Complete Mini EDTA-free). Cell sus-
pensions were spun down for 5 min at 500 rcf at 4uC and washed once in 150 mL
NaPP-buffer (0.1 M, pH 7.4), containing 250 mM sucrose and protease inhibitors
(Complete Mini EDTA-free, Roche). Cells were homogenized by ultra-sonification
and lyophilized. Total protein content was determined by amino acid analysis on an
HPLC system (2695, Waters) using the 6-aminoquinolyl-N-hydroxysccinimidyl
carbamate (AQC) reagent and calculated as described previously29,30.
Peptide Standards. Peptide standards (Thermo Fisher) were quantified by amino
acid analysis on an HPLC system (2695, Waters) using the AccQ Tag derivatisation
protocol (Waters) as described previously29,30.
Protein Digestion. Proteins were precipitated by adding acetone to 80% v/v and were
incubated overnight at 280uC. Samples were centrifuged at 10.000 rcf at 4uC for
5 min. Supernatant was discarded and proteins were air-dried for 5 min. An amount
of 100 fmol per internal standard peptide was added after resolving the proteins in
8 M urea, 0.05% 3-((1-(Furan-2-yl) undecyloxy) carbonylamino) propane-1-
sulfonate (ProteaseMAX, Promega) in 50 mM ammonium bicarbonate pH 7.4.
Proteins were reduced with 5 mM dithiothreitol (DTT) in the presence of 0.05%
ProteaseMAX (Promega) for 20 min at 56uC and alkylated with 15 mM
iodacetamide (IAA) in 50 mM ammonium bicarbonate for 15 min at RT in the dark.
Finally samples were digested with trypsin using an enzyme:substrate ratio of 1510 at
42uC for 4 h on a shaker. Enzymatic reaction was terminated by boiling for 5 min.
Immunoprecipitation. Enzymatically fragmented proteins were mixed with 2 mg
anti-LPNK antibody and incubated at 500 rpm at 30uC for 1 h on a shaker
(Eppendorf). Peptide-antibody complexes were precipitated by adding 10 mL protein
G-coated magnetic microspheres (Invitrogen). Beads were washed using disposable
200 mL pipette tips and a ring magnet. Five wash cycles were performed with 100 mL
PBS, supplemented with 0.3% n-octyl-b-glucoside (SIGMA Aldrich) followed by a
final wash using PBS only. Peptides were eluted by applying 20 mL 1% formic acid.
Peptide desalting. C18 material containing tips (OMIX, Agilent) were pre-
conditioned 5 times with 100 mL 50% acetonitrile and 5 times with 100 mL 0.1%
trifluoric acid (TFA). Peptides were extracted from the sample by pipetting 100 mL 8
times. Peptide elution was carried out in two steps using 15 mL 55% acetonitrile, 0.1%
TFA. The peptide solutions were dried in a vacuum centrifuge and re-solubilized in
25 mL 0.1% TFA, 1% acetonitrile.
LC-SRM. Peptide quantification was performed on a hybrid triple quadrupole ion
trap mass spectrometer (4000QTrap; ABISciex) equipped with a nanoelectrospray
ion source. Prior MS-analysis desalted or immunoprecipitated peptide samples were
separated on a nanoliter flow HPLC system (Ultimate, Dionex) using two precolumn
as described previously31. After injection (15 mL), peptides were trapped and desalted
on a pre-column (0.3 mm I.D. 3 5 mm PepMapTM, Dionex) at a flow rate of 30 mL/
LC-SRMTXP-SRM







































































































Figure 2 | Comparison of signals of endogenous cytochrome P450 3A4/43, (b) 3A5, (c) 3A7, and (d) MDR-1 peptide and synthetic standard. Ten mg
hepatocyte protein extract was digested and spiked with 100 fmol synthetic standard. The samples were either analyzed by TXP-SRM or LC-SRM
workflow. Ion chromatograms of the peptide fragments y3, y4 and y7 are shown.
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min in 0.1% TFA for 6 min. Peptides were transferred to the separation column
(75 mm I.D. 3 250 mm PepMapTM column, Dionex) and separated by applying a
linear gradient of mobile phase (A: 0.1% formic acid, B: 84% acetonitrile/0.1% formic
acid) from 5% B to 40% B over a period of 35 min with a flow of 300 nL/min.
The mass spectrometer was run in multiple-reaction monitoring mode. Peptide-
specific tuned declustering potential (DP), entrance potential (EP), collision cell
energy (CE), collision cell exit potential (CXP), and retention times are given in
supplemental table 2. Three transitions per surrogate peptide were monitored. The
scheduled option was employed for all data acquisition with a target scan time of 3 s,
cycle time of 30 min and an 8 min detection window. Data was processed using
MultiQuant TM 3.0 (ABSciex) applying the MQL algorithm for peak integration.
Retention time window was set to 4 min and a three-point smooth with a peak
splitting factor of 2 applied. No noise subtraction was done. The endogenous amounts
of CYP3A4, CYP 3A5, CYP3A7 and MDR1 were calculated from integrated areas of
the respective ion-chromatogram of the surrogate peptide transitions. Briefly, the
average of the three peak area ratios were formed: internal standard peptide transi-
tions: endogenous peptide transitions.
Epitope analysis by LC-MS. To investigate the specificity of the anti-LPNK antibody
LC-Full-MS analyses of three immunoprecipitation replicates from digested
hepatocyte lysates were performed. We incubated 5 mg anti-LPNK antibody with
50 mg tryptically digested hepatocyte lysate. Peptide antibody complexes were
precipitated with 25 mL protein G-coated magnetic microspheres (Invitrogen).
Peptides were eluted in 20 mL 1% formic acid. The entire eluate (20 mL) was injected
and separated on a nanoliter flow HPLC system (U3000, Dionex). Peptides were
loaded on an Acclaim PepMap100 C18 m-pre-column (0.3 mm I.D. 3 5 mm, 5 mm
particles, Dionex) for 3 min at a flow rate of 20 mL/min in 0.1% TFA. The peptides
were separated for 20 min by an Acclaim PepMap RSLC C18 (75 mm I.D. 3 150 mm,
2 mm particles, Dionex) using a linear gradient from 5% to 55% B at a flow rate of
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Figure 3 | Comparison of integrated signals of endogenous cytochrome P450 3A4 peptide and synthetic standard. One, five, ten or 25 mg hepatocyte
protein extract was digested and spiked with 100 fmol synthetic standard. The samples were either analyzed by TXP-SRM or LC-SRM workflow.
Integrated signals of the peptide fragments y3, y4 and y7 are plotted against the analyzed amount of protein extract.
Table 1 | Intra- and inter-assay variances of the TXP-SRM assays targeting cytochrome P450 3A4, 3A5, 3A7, and multi-drug resistance
protein 1
Replicate [fmol mg21]
Mean (n 5 3) Intra day variation [%]1 2 3
CYP 3A4 13.0 15.1 15.3 14.5 9.0
CYP 3A5 0.7 0.8 0.8 0.7 7.6
CYP 3A7 0.3 0.3 0.3 0.3 10.2
MDR-1 1.1 1.2 1.2 1.2 6.9
Replicate [fmol mg21]
Mean (n 5 3) Inter day variation [%]1 2 3
CYP 3A4 22.6 18.7 15.3 18.9 19.3
CYP 3A5 1.0 0.9 0.8 0.9 11.2
CYP 3A7 0.4 0.4 0.3 0.4 13.2
MDR-1 1.0 1.0 1.2 1.1 8.9
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Orbitrap Mass Spectrometer (Themo Scientific). In MS mode the resolution was set to
70.000, the scan range from 300–2000 m/z, the AGC-target limited to 3e6, and the
injection time to 100 min. For MS2 mode a top 10 method was selected, the precursor
AGC-target limited to 5e5, the maximum injection time set to 60 min, and the
normalized collision energy adjusted to a value of 25%. No underfill ratio was chosen
and only 21, 31, and 41 charged ions included. The dynamic exclusion time was set
to 5.0 s. For identification both Mascot- and SEQUEST-algorithm were chosen for
searching in the UniProt Homo Sapiens Complete Proteome Set database (28 august
2013). Two missed cleavage sites were tolerated. The precursor mass tolerance was set
to 5 ppm, the fragment mass tolerance to 0.05 Da. Carbamidomethylation of cysteins
were allowed as static modification, methionine oxidation as dynamic modification.
For modeling the WebLogo (WebLogo 3, http://weblogo.threeplusone.com/create.
cgi), all peptide identifications of the digest-immunoprecipitation triplicate were
combined. Unspecific peptide binding to antibody and protein G was determined by
analyses of immunoprecipitation experiments using (i) protein G bead and sample
and (ii) protein G-beads and antibody without sample (measured in triplicates).
Those peptides were considered as background and removed from the identification
list. Peptide duplicates were removed. Identifications with at least two identical c-
terminal four-amino acid tags were further considered for modelling the epitope
specificity. The weighting of amino acid presence was related to the total number of
peptide spectrum matches (PSM, ProteomeDiscoverer 1.3, Thermo Scientific) across
the triplicate. Parameters of the WebLogo software were kept default except for
‘‘units’’, which was set to ‘‘probability’’.
Dilution series in buffer. Isotopically-labeled peptides were diluted in digested fish
gelatin, 50 mM Tris-HCI, 150 mM NaCl, and pH 7.4 (Blocking Reagent, Roche)
while sequence-identical endogenous peptides were kept constant at a concentration
of 10 nM. Starting from a concentration of 100 nM, the isotopically-labeled peptides
were serially diluted eight times at a ratio of 153. According to the precipitation
procedure, 10 mL of each dilution step was incubated with 1 mg anti-LPNK. For the
[recommended] peptide sequence, an absolute peptide amount ranging from
1000 fmol to 0.15 fmol was provided for immunoprecipitation.
Dilution series in complex matrix. Isotopically-labeled peptides were diluted in
hepatocyte extract. In an immunoprecipitation procedure, 1 mg anti-LPNK was
incubated with 10 mg digested hepatocyte extract plus an isotopically-labeled peptide
amount ranging from 1000 fmol to 0.15 fmol.
Peptide quantification using LC-coupled targeted Single Ion Monitoring (LC-
tSIM). For quantification, the identical LC-setup was used as described in ‘‘Epitope
analysis by LC-MS’’. Instead of a linear gradient, a step gradient starting at 15% B and
ending after 8 min at 40% B was chosen. On the QExactive Plus Orbitrap Mass
Spectrometer, a tSIM method was applied to quantify peptides at the parent ion level.
The resolution was set to 70,000, the scan range was between 300 and 2000 m/z, and
the AGC target was set at a value of 5e6. The injection time was adjusted to 120 min.
Loop count and MSX count were set to 2 respectively. An inclusion list registering the
masses of endogenous and isotopically-labeled peptides was defined. For ensuring a
high number of data points, the recording time for each signal pair was limited to
0.3 min prior and following the expected elution time. Data-dependent MS/MS was
performed using a resolution of 17,500, an AGC-target of 2e5, and a maximum
injection time of 120 min. The collision energy was set to 30% and the underfill ratio
to 0.6%. For dynamic exclusion, a timeout of 2.0 sec was chosen.
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Figure 4 | Induction of cytochrome P450 3A4, 3A5, 3A7, and multi-drug resistance protein 1. Human hepatoycte cultures (6-well format, 3 days after
isolation) were treated with 60 mM atorvastatin (triangle), 30 mM pravastatin (circle) and solvent control (cross, DMSO) for 6, 12, 24, 48, and 72 hours.
Cells were harvested and homogenized. 10 mg protein extract of each time point was analyzed using the TXP-SRM assays for cytochrome P450 (a) 3A4,
(b) 3A5, (c) 3A7, and (d) multi-drug resistance protein 1.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8759 | DOI: 10.1038/srep08759 6
13. Williamson, B. L. et al. Quantitative protein determination for CYP induction via
LC-MS/MS. Proteomics 11, 33–41 (2011).
14. Kawakami, H. et al. Simultaneous absolute quantification of 11 cytochrome P450
isoforms in human liver microsomes by liquid chromatography tandem mass
spectrometry with in silico target peptide selection. J. Pharm. Sci. 100, 341–352
(2011).
15. Sakamoto, A. et al. Reliability and robustness of simultaneous absolute
quantification of drug transporters, cytochrome P450 enzymes, and Udp-
glucuronosyltransferases in human liver tissue by multiplexed MRM/selected
reaction monitoring mode tandem mass spectrometry with nano-liquid
chromatography. J. Pharm. Sci. 100, 4037–4043 (2011).
16. Jenkins, R. E. et al. Relative and absolute quantitative expression profiling of
cytochromes P450 using isotope-coded affinity tags. Proteomics 6, 1934–1947
(2006).
17. Langenfeld, E., Zanger, U. M., Jung, K., Meyer, H. E. & Marcus, K. Mass
spectrometry-based absolute quantification of microsomal cytochrome P450 2D6
in human liver. Proteomics 9, 2313–2323 (2009).
18. Simicevic, J. et al. Absolute quantification of transcription factors during cellular
differentiation using multiplexed targeted proteomics. Nat. Methods 10, 570–576
(2013).
19. Lewis, D. F. 57 varieties: the human cytochromes P450. Pharmacogenomics 5,
305–318 (2004).
20. Schaefer, O. et al. Absolute quantification and differential expression of drug
transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in
cultured primary human hepatocytes. Drug Metab. Dispos. 40, 93–103 (2012).
21. A Guidance for Industry - Bioanalytical method validation. US Food and Drug
Administration (2001).
22. Feidt, D. M. et al. Profiling induction of cytochrome p450 enzyme activity by
statins using a new liquid chromatography-tandem mass spectrometry cocktail
assay in human hepatocytes. Drug Metab. Dispos. 38, 1589–1597 (2010).
23. Geick, A., Eichelbaum, M. & Burk, O. Nuclear receptor response elements mediate
induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276, 14581–14587
(2001).
24. Burk, O. et al. Molecular mechanisms of polymorphic CYP3A7 expression in
adult human liver and intestine. J. Biol. Chem. 277, 24280–24288 (2002).
25. Chu, V. et al. In vitro and in vivo induction of cytochrome p450: a survey of the
current practices and recommendations: a pharmaceutical research and
manufacturers of america perspective. Drug Metab. Dispos. 37, 1339–1354 (2009).
26. Bucher, J. et al. A systems biology approach to dynamic modeling and inter-
subject variability of statin pharmacokinetics in human hepatocytes. BMC Syst.
Biol. 5, 66 (2011).
27. Thasler, W. E. et al. Charitable State-Controlled Foundation Human Tissue and
Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed
Human Tissue For Research in the Academic and Commercial Sector in
Germany. Cell Tissue Bank. 4, 49–56 (2003).
28. Nussler, A. K. et al. in Strategies in Regenerative Medicine. (ed. Santin, M.)
(Springer, New York, 2008).
29. Cohen, S. A. & Michaud, D. P. Synthesis of a fluorescent derivatizing reagent, 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate, and its application for the
analysis of hydrolysate amino acids via high-performance liquid
chromatography. Anal. Biochem. 211, 279–287 (1993).
30. Plum, S. et al. Combined enrichment of neuromelanin granules and synaptosomes
from human substantia nigra pars compacta tissue for proteomic analysis.
J. Proteomics 94, 202–206 (2013).
31. Schaefer, H. et al. A peptide preconcentration approach for nano-high-
performance liquid chromatography to diminish memory effects. Proteomics 4,
2541–2544 (2004).
Acknowledgments
This work was funded by the German Federal Ministry of Education and Research (BMBF;
grant FKZ 0315742 to M.F.T. and T.O.J. (Virtual Liver), grant FKZ 031A142 to F.W. and
O.P. (GO-Bio), and grant FKZ 0313080 to A.S., M.R., A.K.N., T.S.W., W.E.T. and K.M.
(HepatoSys network project)).
Author contributions
F.W., A.S., M.F.T., T.O.J., K.M. and O.P. conceived and planned the experiments. F.W.,
O.P., A.S., M.R. and B.S. performed experiments. A.K.N., W.E.T. and T.S.W. isolated
hepatocytes. O.P., A.S., H.P., B.B., D.S. and F.W. performed data analysis. O.P. and K.M.
prepared the manuscript. All authors discussed the results and commented on the paper.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Weiß, F. et al. Indirect protein quantification of drug-transforming
enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry.
Sci. Rep. 5, 8759; DOI:10.1038/srep08759 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce the material. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8759 | DOI: 10.1038/srep08759 7
